Cannabis oil: what is it and does it really work as
Cannabis oil: what is it and does it really work as medicine?
Cannabis oil has come under scrutiny
By Alison George
Cannabis is in the headlines for its potential medical benefits after the recent confiscation of cannabis oil medication from the mother of a 12-year-old British boy with severe epilepsy. The furore that ensued is shining a light on campaigns for cannabis oils to be made legal for medical reasons, and the UK government has now announced a review into the use of medicinal cannabis. Here’s what you need to know.
What is cannabis oil?
Cannabis oil is extracted from the cannabis plant Cannabis sativa. The plants medicinal properties have been touted for more than 3,000 years. It was described in the ancient Eygyptian Ebers papyrus around 1550BC, and it was likely used as a medicine in China before that. Some varieties of the plant contain high levels of the psychoactive substance tetrahydrocannabinol (THC), which is responsible for the “high” that comes from smoking or eating cannabis leaves or resin. The plant’s other major chemical component is cannabidiol, which has no psychoactive effect. Both act on the body’s natural cannabinoid receptors which are involved in many processes such as memory, pain and appetite. The cannabis plant also contains more than 100 other different cannabinoid compounds at lower concentrations.
So can cannabis oil make you high?
It depends on the THC content. Some types of Cannabis sativa plant, known as hemp, contain very little THC. The extracts from these plants contain mainly cannabidiol, so will not get anyone stoned.
Is it legal?
That’s a complicated question. In the UK cannabidiol is legal. Cannabis plant extracts (known as hemp or CBD oils) are available in high-street stores but the THC content must be below 0.2 per cent. “THC is not psychoactive at this level,” says David Nutt, a neuropsychopharmacologist at Imperial College London. But cannabidiol is illegal in many other countries.
In the USA for example, cannabidiol is classed as a schedule 1 controlled substance, and can only be sold in states where cannabis use is legal.
However, the tide may turn in favour of cannabidiol after a recent World Health Organisation review. This concluded that cannabidiol “exhibits no effects indicative of any abuse or dependence potential” but “has been demonstrated as an effective treatment of epilepsy … and may be a useful treatment for a number of other medical conditions.”
What is the evidence that cannabis oils can help treat epilepsy?
Although there is some scientific evidence that THC has potential to control convulsions, its mind-altering effects mean that much of the focus has turned to cannabidiol – particularly for childhood epilepsies that conventional drugs fail to control.
Ads by ZINC
Two recent high quality randomised and placebo controlled trials showed that cannabidiol is an effective treatment for Lennox-Gastaut syndrome and Dravet syndrome, severe forms of epilepsy. The mechanism of action is unknown, but it may be due to a combination of effects, such as inhibiting the activity of neurons and dampening inflammation in the brain.
The situation is less clear when it comes to the use of commercial cannabis oils to control seizures, where the evidence is mainly anecdotal, and the oils can contain differing concentrations of cannabidiol and THC.
The UK government announced on 19 June that it would review the use of medical cannabis.
Are there any cannabis-based epilepsy drugs on the market?
Not yet. In April the US Food and Drug Administration recommended the approval of a drug called Epidiolex for Lennox-Gastaut syndrome and Dravet syndrome. Its active ingredient is cannabidiol, and final approval is due at the end of this month.
However, it is possible the drug is not as effective as cannabis oil containing THC, says Nutt. For example, the cannabis oil used to treat Billy Caldwell, the boy at the centre of the recent cannabis oil confiscation furore, contained cannabidiol and a low dose of THC, because cannabidiol alone did not stop all his seizures.
This is one of the big unknowns. “It is important to remember that there is currently very little scientific evidence to support cannabis oil containing both THC and cannabidiol as a treatment for epilepsy,” said the charity Epilepsy Action, in a statement issued this month.
Are cannabis-based medications available for other conditions?
Yes. A synthetic version of THC called Nabilone has been used since the 1980s to treat nausea after chemotherapy and to help people put on weight. A drug called Sativex is also approved for the treatment of pain and spasms associated with multiple sclerosis. It contains an equal mix of THC and cannabidiol, but would not be suitable for the treatment of children with epilepsy such as Billy. “If you used that to treat epilepsy, the kids would be stoned off their heads,” says Nutt.
What is the aim of the UK government’s review of medical cannabis?
The first part of the review will look at the evidence for the therapeutic value of cannabis-based products. It can recommend any promising ones for the second part of the review. This will be carried out by the government’s Advisory Council for the Misuse of Drugs, which can recommend a change to the legal medical status of cannabis and cannabinoids.
This will hopefully lead to a relaxation of the rules surrounding research into cannabis-based medicines says Tom Freeman, a clinical psychopharmacologist at King’s College London.
In the UK cannabis currently has Schedule 1 status, the most restrictive category, which is for drugs which are not used medicinally such as LSD. “This creates a Catch 22 situation,” says Freeman. “You can’t show that cannabis and cannabis-based products have medicinal value because of restrictions on medical research.” If cannabis is moved to the Schedule 2 category, it will join substances such as morphine and diamorphine (heroin) which can be prescribed by doctors if there is a clinical need.
Read more: Some people with epilepsy can learn to stop their own seizures
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...
Continue Reading
Preserving the Tunes of the Bayou Well, if that ain't music to your ears! The Louisiana First Horizon Foundation is sliding into the spotlight with news that's bound to strike a chord with any lover of the state's iconic rhythms. They're diving in deep, backing the Louisiana Music Museum right in the heart of Lafayette. Now, that ain't just another charity stunt; it's a...
Continue Reading
Where Did It All Go Wrong for Tenax? They say the stock market is a rollercoaster, but Tenax Therapeutics, Inc. (NASDAQ: TENX) seems to have taken that expression way too literally. Imagine watching your investments tumble by nearly 90% in a single day. On August 10, 2026, that was the grim reality for Tenax's stockholders when the company's shares plummeted from over $13...
Continue Reading
A New Chapter for Auto Retail with AI Well, here's something stirring the pot in the auto industry—a unified action system by IDP that's combining humans and AI agents to drive better business outcomes. It's like getting an extra shot of espresso in your morning coffee, but for business execution. This isn't just another soft pitch about artificial intelligence either;...
Continue Reading
Diving into AZZ's Sustainability Commitment AZZ Inc., known in the trading circles as NYSE:AZZ, has just dropped its 2026 Sustainability Report and it’s quite the document to chew on. This ain't your typical corporate fluff. Tom Ferguson, the man steering the AZZ ship, laid it down plain and simple. This report isn’t just about ticking boxes for ESG; it’s reflecting...
Continue Reading
Breaking Ground: Education Made Accessible Boy, oh boy, this move between Mount St. Mary’s University and Saint John Vianney High School is something that just warmed up my trading heart like a surprise market rally. They've inked a deal—a Memorandum of Understanding (MOU)—to fling open the doors to higher education for high schoolers who've got their eyes on the...
Continue Reading
FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...
Continue Reading
Setting Sail on Savings: Princess Cruises' Offerings When folks start talking about Black Friday, you probably think of TVs or gadgets, but Princess Cruises is flipping that idea with their 'Blue Friday' sale, running from November 6 through December 7, 2026. Now, cruises aren't your traditional doorbuster, but a vacation might just be the kind of experience worth...
Continue Reading
A Family's Heartfelt Request in the Face of Tragedy Sometimes life deals in blows that are as sudden as they are incomprehensible. This is one of those times for the Pendas family. Tomas Pendas, a Miami native and the heart behind Global Air Group, tragically passed away in a helicopter crash on November 4th, 2026 near Nixon Beach in Biscayne Bay. Looking Back: Tomas...
Continue Reading
Legal Storms Gather on Pinterest's Horizon I remember a time when Pinterest was the darling of Wall Street, but here we are, staring at an investigation that's got more layers than an onion. On November 6, 2026, news broke that Kahn Swick & Foti, LLC (KSF) is sniffing around Pinterest's officers and directors. This is no small fry since KSF is steered by none other than...
Continue Reading
Top 5 Most Recently Viewed Articles
AeroVironment in Hot Water: Legal Actions and Investor Moves Buckle up, investors, because AeroVironment's roller coaster isn't pulling into the station anytime soon. The latest buzz is that if you've watched your AeroVironment (NASDAQ: AVAV) holdings evaporate amid the recent chaos, you'd better circle July 27, 2026, on your calendar. That's your last call to jump into...
Continue Reading
Christ is King: A Movement Towards Faith and Technology Christ is King ($CIK) is not merely a concept; it’s a transformative movement aimed at integrating the Christian community into the dynamic world of Web3. The movement recently unveiled its exciting community roadmap, encapsulating its mission to onboard an impressive one million Christians into this new digital...
Continue Reading
Congressman with a Nose for Small-Cap Opportunities Investors keep a keen eye on members of Congress, especially when someone like Tim Moore steps into the spotlight again. This guy's got a track record for sniffing out small-cap gems, and it seems 2026 is shaping up to be no different. We're talking about Genprex (GNPX) and Simply Good Foods (SMPL), both of which are...
Continue Reading
Exciting Opportunities for Panacea Healthcare Solutions at HFMA Conference Panacea Healthcare Solutions is thrilled to engage in the upcoming 49th Annual New Jersey and Metro Philadelphia HFMA Conference. This esteemed event provides a platform for innovators and leaders in healthcare finance to come together and discuss current challenges and best practices. As a...
Continue Reading
Funding Suspended by the Trump Administration The Trump administration has taken a significant step by halting over $10 billion in funding aimed at social services and child care in several Democratic-led states. This decision comes amid growing concerns about potential fraud regarding the allocation of these funds to individuals who may not be U.S. citizens. Fraud...
Continue Reading